☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Lymphoma
TG Therapeutics' Ukoniq (umbralisib) Receives the US FDA's Approval for R/R Marginal Zone Lymphoma and Follicular Lymphoma
February 2, 2021
MorphoSys' Monjuvi (tafasitamab-cxix) + Lenalidomide Receives the US FDA's Approval as 2L Treatment for Patients with Relapsed or...
August 3, 2020
Celltrion Report Results of Truxima (biosimilar- rituximab) Based Regimen in P-II Study for R/R Aggressive B-cell Lymphoma #EHA25
June 16, 2020
Roche's Polivy (polatuzumab vedotin) Based Combination Regimen Receives EC's Approval for Patients with R/R Diffuse Large B-Cell L...
January 21, 2020
Roche's Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA's Accelerated Approval for Relapsed/Refractory Lymphoma
June 11, 2019
Bayer's Aliqopa (copanlisib) Receives the US FDA's Breakthrough Therapy Designation to Treat Marginal Zone Lymphoma in Adults
May 29, 2019
Load more...
Back to Home